Results 251 to 260 of about 198,039 (308)

Pembrolizumab and SBRT for vaginal cuff recurrence of endometrial carcinoma with regression beyond the radiation field. [PDF]

Gynecol Oncol Rep
Fazal M, Mao S, Armstrong D, Viswanathan AN.   +3 more
europepmc   +1 more source

A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Enterocolitis is a common gastrointestinal manifestation of immune‐related adverse events (irAEs); however, only a few studies have reported on irAE enteritis with localized active inflammation in the small intestine. Here, we report the case of a 74‐year‐old man who developed diarrhea, abdominal pain, and oral intake difficulty and was ...
Ryo Morikawa, Ryosuke Kanaya, Hiromichi Shimizu, Masayoshi Fukuda, Yasuhiro Nemoto, Toshimitsu Fujii, Towako Taguchi, Kurara Yamamoto, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
wiley   +1 more source

Efficacy of continuing pembrolizumab after progression on first-line treatment in stage IV non-small cell lung cancer: a prospective real-world study. [PDF]

Am J Cancer Res
Ruan K, Lv X, Wu X, Shao J, Chen P, Sun D, Tang Y, Wang B, Ding Y, Han Z, Huang W, Wu D, Xu Y, Zheng J, Qu J, Zhou J, Zhou J.   +16 more
europepmc   +1 more source

Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review

International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi, Adrian Tabari, Jeffrey Donovan   +2 more
wiley   +1 more source

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Recently, zolbetuximab combined with chemotherapy has been approved as a first‐line treatment for advanced gastric cancer (GC). However, to date, no endoscopic images demonstrating endoscopic complete response (eCR) to zolbetuximab plus chemotherapy have been reported.
Akinori Sasaki, Tomohiro Yamaba, Ayu Tachibana, Rika Kimura, Gaku Uchiyama, Tsubasa Yoshioka, Risa Okamoto   +6 more
wiley   +1 more source

Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer. [PDF]

Gynecol Oncol
Patterson B, Sinha N, Broaddus E, Stocks S, Zamboni W, Albright BB, Gehrig P, Bae-Jump V, Lara OD.   +8 more
europepmc   +1 more source

Dilation Device Use and Concomitant Antegrade Stenting are Associated With Procedure‐related Early Adverse Events After Endoscopic Ultrasound‐guided Hepaticogastrostomy: A Retrospective Multicenter Study

DEN Open, Volume 6, Issue 1, April 2026.
This multicenter study identified use of dilation devices and antegrade stenting are risk factors for procedure‐related early adverse events following endoscopic ultrasound‐guided hepaticogastrostomy. ABSTRACT Objectives Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) is useful in cases of endoscopic retrograde cholangiopancreatography ...
Shinichi Hashimoto, Hiroki Taguchi, Norimasa Araki, Yu Yamazato, Hiroki Iwata, Yuji Tabira, Ryusuke Shibata, Yusuke Kamikihara, Koshiro Toyodome, Issei Kojima, Takafumi Hamada, Kengo Tsuneyoshi, Yoshitaka Nakamura, Hiroki Yano, Makoto Hinokuchi, Shiho Arima, Shiroh Tanoue, Fumisato Sasaki, Shuji Kanmura, Akio Ido   +19 more
wiley   +1 more source

Impact of melanoma histological regression on first‐line immunotherapy response in stage‐IV disease

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jean‐Baptiste Such, Sandrine Mansard, Mélissa Zlobecki, Carole Chevenet, Céline Lambert, Marie Bachelerie, Jacques Rouanet   +6 more
wiley   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Pembrolizumab-Induced Choriocapillaritis and Orbital Inflammation: A Case Report. [PDF]

Cureus
El Korno O, Hilali Z, Boutaj T, El Ghazi H, Benchekroun S, Tachfouti S, Amazouzi A, Cherkaoui LO.   +7 more
europepmc   +1 more source